Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Collaborative normal tension glaucoma study.

Douglas R Anderson1,

  • 1Department of Opthalmology, University of Miami School of Medicine, Miami, Florida 33101-6880, USA. danderson@med.miami.edu

Current Opinion in Ophthalmology
|April 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fractional averaging theory for discrete fractional-order system with impulses.

Chaos (Woodbury, N.Y.)·2024
Same author

Clinical Application of the 20-Year Results from the Ocular Hypertension Treatment Study.

JAMA ophthalmology·2021
Same author

Planning Clinical Research and Clinical Care for Different Rates of Glaucoma Progression.

JAMA ophthalmology·2021
Same author

Thirty Years of Glaucomatous Damage with Normal Intraocular Pressure.

Ophthalmology. Glaucoma·2020
Same author

Separation and thickness measurements of superficial and deep slabs of the retinal nerve fiber layer in healthy and glaucomatous eyes.

Ophthalmology. Glaucoma·2020
Same author

Clinical Recognition of Glaucomatous Cupping.

American journal of ophthalmology·2018
Same journal

Laser vision correction (LASIK, PRK, SMILE) with simultaneous accelerated corneal crosslinking.

Current opinion in ophthalmology·2026
Same journal

Traumatic macular hole: observe, operate, or other options.

Current opinion in ophthalmology·2026
Same journal

The evolving role of artificial intelligence in ophthalmology: basic science, translation, and clinical integration.

Current opinion in ophthalmology·2026
Same journal

Editorial: reducing risk for refractive surgery.

Current opinion in ophthalmology·2026
Same journal

Updates on Refractive Surgery: Benefits, Risks, and Costs of Modern Treatment Options.

Current opinion in ophthalmology·2026
Same journal

Corneal Allogeneic Intrastromal Ring Segments for keratoconus - recent evidence and the move to customized and custom shaped CAIRS.

Current opinion in ophthalmology·2026
See all related articles

Lowering intraocular pressure (IOP) can slow vision loss in normal tension glaucoma. Individualized treatment plans are crucial, considering disease stage and progression rate for optimal outcomes.

Area of Science:

  • Ophthalmology
  • Neuroscience

Background:

  • Normal tension glaucoma (NTG) is characterized by optic nerve damage and visual field loss despite statistically normal intraocular pressure (IOP).
  • A historical debate existed regarding IOP's role in NTG pathogenesis.

Purpose of the Study:

  • To review findings from a collaborative study investigating the impact of IOP on optic nerve damage in NTG.
  • To clarify the relationship between IOP levels and glaucomatous progression in normal tension glaucoma.

Main Methods:

  • Review of findings from a collaborative study on normal tension glaucoma.
  • Analysis of factors influencing disease progression and treatment response.

Main Results:

  • Lowering IOP by 30% or more significantly slows visual field loss in NTG patients.

Related Experiment Videos

  • Disease progression is variable, with many patients showing no progression over 5 years without treatment.
  • Factors such as female sex, migraine headaches, and disc hemorrhages are associated with faster progression.

    • Conclusions:

    • Patients with NTG generally benefit from IOP reduction.
    • Individualized treatment strategies are essential, considering disease severity and progression rate.
    • Further research is needed to identify specific patient subgroups who will most benefit from IOP-lowering treatments.